CN110108877B - Application of FAM172A autoantibody detection reagent in preparation of lung cancer screening kit - Google Patents
Application of FAM172A autoantibody detection reagent in preparation of lung cancer screening kit Download PDFInfo
- Publication number
- CN110108877B CN110108877B CN201910466523.8A CN201910466523A CN110108877B CN 110108877 B CN110108877 B CN 110108877B CN 201910466523 A CN201910466523 A CN 201910466523A CN 110108877 B CN110108877 B CN 110108877B
- Authority
- CN
- China
- Prior art keywords
- fam172a
- lung cancer
- reagent
- autoantibody
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 46
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 46
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 46
- 102100022615 Cotranscriptional regulator FAM172A Human genes 0.000 title claims abstract description 41
- 101000823488 Homo sapiens Cotranscriptional regulator FAM172A Proteins 0.000 title claims abstract description 41
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 35
- 238000012216 screening Methods 0.000 title claims abstract description 16
- 238000001514 detection method Methods 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 210000002966 serum Anatomy 0.000 claims abstract description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000002965 ELISA Methods 0.000 claims description 4
- 238000001262 western blot Methods 0.000 claims description 3
- 239000000439 tumor marker Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 238000011534 incubation Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 208000019693 Lung disease Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013075 data extraction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4746—Cancer-associated SCM-recognition factor, CRISPP
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a FAM172A autoantibody detection reagent in preparation of a lung cancer screening kit. The invention discovers for the first time that the level of autoantibodies of FAM172A protein in the serum of a lung cancer patient is obviously higher than that of a healthy patient. According to the invention, the reagent for detecting the FAM172A protein autoantibody is used for preparing the lung cancer screening kit, so that effective screening of lung cancer can be realized.
Description
Technical Field
The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a FAM172A autoantibody detection reagent in preparation of a lung cancer screening kit.
Background
Lung cancer is one of the most common malignant tumors in the world, the morbidity and mortality of the lung cancer are on the rising trend year by year, the morbidity is at the top of the world at present, and the health and the life of human beings are seriously threatened.
The lung cancer is a disease good in occult, clinical symptoms are often shown only when the disease develops to the advanced stage, 70-80% of lung cancer patients are already at the middle and advanced stages when the lung cancer symptoms are diagnosed, cancer cells are diffused, the best curing time is missed, and the five-year survival rate is low. For early-stage lung cancer patients, the survival rate and the survival quality of the patients can be greatly improved by 5 years and more through timely treatment. Early diagnosis of lung cancer and effective screening are therefore of paramount importance.
The screening of the lung cancer refers to that the conventional physical examination is carried out on people without lung cancer related symptoms, and the lung cancer is found in time before the symptoms appear. If the lung cancer molecular marker in the plasma can be found, the molecular marker has important significance for prompting a clinician to take relevant treatment measures or decisions for a patient at an early stage.
Autoantibodies are antibodies produced by the body to self-organs, cells or cellular components. At present, autoantibodies to certain proteins have become markers for lung cancer, such as: p53, NY-ESO-1, CYFRA, etc. (Tang Z-M, Link Z-G, WangC-M, Wu Y-B, Kong J-L (2017) Serum tune-associated autoimmune agents as diagnostic biologics for lung cancer: A systematic review and meta-analysis. PLoS ONE 12 (7): e 0182117).
FAM172A (Ensembl: ENSG00000113391) protein has been reported to be involved in cancer, for example, it can aggravate development of papillary thyroid cancer (FAM172A protein proteins of the promotion of papillary thyroid cancer cells of the p38 mitogen-activated protein kinase pathway. mol Med. Rep. Jan; 13 (1): 353-8.), and also can be used as an anti-cancer factor for colorectal cancer (FAM172A a promoter in general cancer. Tumour biol. 2016May; 37 (5): 6501-10.). However, reports related to FAM172A protein autoantibodies are not found at present, and the prior art related to lung cancer is not found.
Disclosure of Invention
The invention aims to provide a novel autoantibody lung cancer marker and application of a detection reagent of the marker in preparation of a lung cancer screening kit.
The technical scheme of the invention comprises the following steps:
the application of the reagent for detecting the FAM172A protein autoantibody in preparing a lung cancer screening kit.
As the application, the reagent for detecting the FAM172A protein autoantibody is a reagent for enzyme-linked immunosorbent assay or a combined immunoassay reagent.
As for the application, the reagent for detecting the FAM172A protein autoantibody is a western blot reagent.
As mentioned above, the reagent for detecting FAM172A protein autoantibody is a reagent for protein chip detection method.
As for the application, the reagent for detecting the FAM172A protein autoantibody is a reagent for detecting the FAM172A protein autoantibody in human serum.
A lung cancer screening kit, which comprises a reagent for detecting FAM172A protein autoantibody.
As the kit, the reagent for detecting the FAM172A protein autoantibody is a reagent for enzyme-linked immunosorbent assay or an enzyme-linked immunoassay reagent.
As the kit, the reagent for detecting the FAM172A protein autoantibody is a western blot reagent.
As the kit, the reagent for detecting the FAM172A protein autoantibody is a reagent for a protein chip detection method.
As the kit, the reagent for detecting the FAM172A protein autoantibody is a reagent for detecting the FAM172A protein autoantibody in human serum.
The invention provides a new lung cancer screening marker and a new lung cancer screening kit, which can realize effective screening of lung cancer; and the serum can be used as a detection sample, so that the harm to a patient is low. The invention has good application prospect.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The foregoing aspects of the present invention are explained in further detail below with reference to specific embodiments. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Hereinafter, "FAM 172A autoantibody" refers to "FAM 172A protein autoantibody".
Drawings
FIG. 1: lung cancer patients (LC), benign lung Disease (DC), healthy control (NC) plasma levels of FAM172A autoantibodies were compared.
FIG. 2: ROC analysis of lung cancer patients (LC) and benign lung Disease (DC).
FIG. 3: lung cancer patients (LC) were analyzed by ROC with healthy controls (NC).
Detailed Description
Example 1 relationship between FAM172A autoantibodies and Lung cancer in plasma
First, clinical data
30 lung cancer patients, 29 lung benign diseases (non-malignant tumors such as tuberculosis and hamartoma) and 30 healthy controls are selected, and the basic information is as follows:
second, detection principle
HuProtTMThe human protein customizing chip is fixed with FAM172A protein, after the human protein customizing chip is incubated by adding serum, FAM172A autoantibodies (mainly comprising IgG and IgM antibodies and also some other types of antibodies) in the serum can be combined, the unbound antibodies and other proteins are removed by cleaning, an anti-human IgM fluorescent labeled secondary antibody (cy5 labeled and red) and an anti-human IgG fluorescent secondary antibody (cy3 labeled and green) are used for detection, signals are read by a fluorescence scanner, and the strength of the signals is positively correlated with the affinity and the quantity of the antibodies.
Third, method
1) Rewarming: taking out the chip from a refrigerator at-80 deg.C, putting in a refrigerator at 4 deg.C for rewarming for half an hour, and then putting in room temperature for rewarming for 15 min;
2) and (3) sealing: fixing 14 blocks in the rewarming chip, adding sealing liquid into each block after fixing, placing on a side swing bed, and sealing at room temperature for 3 hr;
3) incubation of serum samples: after sealing is finished, pouring the sealing liquid completely, then quickly adding a serum incubation liquid prepared in advance, wherein each chip can incubate 14 serum samples, the sample loading volume of each serum sample is 200 mu L, and the shaking table is laterally swung at 20rpm and incubated overnight at 4 ℃ (the serum samples are firstly put in a chromatography cabinet at 4 ℃ for freeze thawing, and the incubation liquid is added to dilute in a ratio of 1: 50 to obtain the serum incubation liquid);
4) cleaning: the chip and the chip fence are taken out together, the sample is sucked, then the PBST with the same volume is added rapidly, and the cycle is repeated for a plurality of times, so that no cross contamination exists among the serum samples when the chip fence is detached. After the chip fence is removed, the chip is placed in a chip cleaning box with cleaning solution, and is cleaned for 3 times (10 min each time) by a horizontal shaking table at room temperature of 80 rpm;
5) and (3) secondary antibody incubation: transferring the chip into an incubation box added with 3mL of secondary antibody incubation liquid, laterally swinging a shaker at 40rpm, keeping out of the sun, and keeping at room temperature for 1 hr;
6) cleaning: the chip was removed (note that the upper surface of the chip was not touched or scratched), and placed in a chip washing cassette containing a washing solution, and washed 3 times 10min each time, on a horizontal shaker at room temperature and 80 rpm. After the completion, the mixture is washed for 2 times for 10min by ddH 2O;
7) drying;
8) scanning: scanning by using a crystal core LuxScan 10K microarray chip scanner;
9) data extraction: opening the corresponding GAL file (recording the position of protein in the chip), aligning the chip image and each array of the GAL file integrally, pressing an automatic alignment button, extracting data and storing.
Fourthly, the result
The mean expression level of FAM172A autoantibodies in the plasma of lung cancer patients was 45.95 SNR (fluorescence signal relative quantitative ratio), the mean expression level of FAM172A autoantibodies in the plasma of benign lung disease was 30.61 SNR, and the mean expression level of FAM172A autoantibodies in the plasma of healthy control was 27.38 SNR. The lung cancer group was statistically significant compared to the benign lung disease group (p < 0.05) and the healthy control group (p < 0.05) (FIG. 1). The specificity of ROC analysis of lung cancer group and benign disease was 96.5%, and the sensitivity was 13.8% (FIG. 2); the results of ROC analysis of lung cancer groups versus healthy controls gave specificity of 96.5% and sensitivity of 27.6% (FIG. 3), indicating that FAM172A autoantibodies specifically distinguished lung cancer from benign lung disease versus healthy controls.
From the above results, it is clear that the difference in the level of FAM172A autoantibodies in the serum of lung cancer patients and non-lung cancer patients is significant, and the purpose of lung cancer screening can be achieved by detecting the level of FAM172A autoantibodies in the serum.
EXAMPLE 2 composition of the detection kit of the invention and method of use thereof
Kit composition
Detection kit (14 persons):
second, kit using method
Same as example 1, third part- "detection of FAM172A autoantibodies in serum".
The kit can screen the risk of lung cancer of a human to be detected by detecting the level of the FAM172A autoantibody in serum: the risk of lung cancer is high if FAM172A autoantibody levels are high (relative to healthy humans), and low if FAM172A autoantibody levels are low. The method can be used for the auxiliary diagnosis of clinical lung cancer, provides effective basis for patients to take relevant treatment measures or decisions, and has good clinical application prospect.
Claims (4)
1. The application of a reagent for detecting FAM172A protein autoantibody in preparing a lung cancer screening kit;
the kit takes FAM172A autoantibody as a unique lung cancer marker;
the autoantibodies are IgM and IgG;
the kit takes serum as a detection sample.
2. The use according to claim 1, wherein the reagent for detecting the FAM172A protein autoantibody is a reagent for enzyme-linked immunosorbent assay.
3. The use according to claim 1, wherein the reagent for detecting the FAM172A protein autoantibody is a western blot reagent.
4. The use according to claim 1, wherein the reagent for detecting the FAM172A protein autoantibody is a reagent for a protein chip detection method.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910466523.8A CN110108877B (en) | 2019-05-30 | 2019-05-30 | Application of FAM172A autoantibody detection reagent in preparation of lung cancer screening kit |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910466523.8A CN110108877B (en) | 2019-05-30 | 2019-05-30 | Application of FAM172A autoantibody detection reagent in preparation of lung cancer screening kit |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110108877A CN110108877A (en) | 2019-08-09 |
CN110108877B true CN110108877B (en) | 2020-06-16 |
Family
ID=67493154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910466523.8A Active CN110108877B (en) | 2019-05-30 | 2019-05-30 | Application of FAM172A autoantibody detection reagent in preparation of lung cancer screening kit |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110108877B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110850088B (en) * | 2019-12-06 | 2021-08-20 | 四川大学华西医院 | Application of GTF2IRD2 autoantibody detection reagent in preparation of lung cancer screening kit |
CN110873798A (en) * | 2019-12-09 | 2020-03-10 | 四川大学华西医院 | Application of PPFIA4 autoantibody detection reagent in preparation of lung cancer screening kit |
CN112415198B (en) * | 2020-11-20 | 2022-11-11 | 四川大学华西医院 | Application of GP1BB detection reagent in preparation of lung cancer screening kit |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2726531A1 (en) * | 2008-06-05 | 2009-12-10 | University Health Network | Compositions and methods for classifying lung cancer and prognosing lung cancer survival |
WO2017123648A1 (en) * | 2016-01-12 | 2017-07-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Plasma autoantibody biomarkers for diagnosis of lung cancer |
WO2018187228A1 (en) * | 2017-04-03 | 2018-10-11 | Cdi Laboratories, Inc. | Serological biomarkers for early diagnosis of lung cancer |
CN109116024B (en) * | 2018-06-14 | 2021-04-23 | 郑州大学第一附属医院 | Lung cancer marker anti-ACTR 3 autoantibody and application thereof |
-
2019
- 2019-05-30 CN CN201910466523.8A patent/CN110108877B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN110108877A (en) | 2019-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110108879B (en) | Application of ERP27 autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110108877B (en) | Application of FAM172A autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110836968A (en) | Application of C9ORF45 autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110456064B (en) | Application of SARS2 autoantibody detection reagent in preparing lung cancer screening reagent kit | |
CN110596389B (en) | Application of ESRP1 autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110850088B (en) | Application of GTF2IRD2 autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110456067B (en) | Application of EHD2 autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110632317A (en) | Application of SAMHD autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110596390A (en) | Application of EEF2K autoantibody detection reagent in preparation of lung cancer detection kit | |
CN110632309A (en) | Application of CHAMP1 autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110632315A (en) | Application of MSI1 autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110554192B (en) | Application of LIMCH1 autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110596386B (en) | Application of EGFLAM autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110749733B (en) | Application of TGIF2LY autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110632308B (en) | Application of CASP8 autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110596387B (en) | Application of COX10 autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110456079B (en) | Application of TAPBP autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110850089B (en) | Application of SARS autoantibody detection reagent in preparing lung cancer screening reagent kit | |
CN110554191B (en) | Application of FAM120B autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110632312B (en) | Application of A1CF autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110780073B (en) | Application of SPANXN3 autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110412277B (en) | Application of SNAP91 autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110412272B (en) | Application of ALKBH3 autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110456061B (en) | Application of RUNDC3A autoantibody detection reagent in preparation of lung cancer screening kit | |
CN110412273B (en) | Application of CAAP1 autoantibody detection reagent in preparation of lung cancer screening kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |